一、中文名称：度普利尤单抗
二、产品描述：Dupilumab（度普利尤单抗） 是一种潜在首创的（first-in-class），针对 IL-4 受体α (IL-4Rα) 的完全人源化的单克隆抗体，可抑制 IL-4 和 IL-13 信号转导，能用于特应性皮炎和哮喘的相关研究。
三、产品详情
货号：DHD62601
表达系统：Mammalian Cells
种属反应性：Human
宿主：Human
同种型：IgG4-kappa
克隆类型：Monoclonal
靶标：IL-4RA, IL-4-binding protein, IL-4 receptor subunit alpha, Soluble IL-4R-alpha, IL4-BP, IL4R, IL-4R subunit alpha, IL-4R-alpha, CD124, Interleukin-4 receptor subunit alpha, IL4RA, Soluble IL-4 receptor subunit alpha, sIL4Ralpha/prot
浓度：2.86 mg/ml
内毒素水平：Please contact with the lab for this information.
纯度：>95% as determined by SDS-PAGE.
纯化方式：Protein A/G purified from cell culture supernatant.
Accession 号：P24394
克隆号：Dupilumab
应用：Research Grade Biosimilar
状态：Liquid
保存溶液：0.01M PBS, pH 7.4.
稳定性和存储：Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
别名：CD124, REGN668, SAR231893, CAS: 1190264-60-8
四、参考文献：
Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps. PMID: 32240527
Dupilumab in Dermatology: Potential for Uses Beyond Atopic Dermatitis. PMID: 31603635
Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma. PMID: 36958470
Predicting dupilumab treatment outcome in patients with primary diffuse type 2 chronic rhinosinusitis. PMID: 36161658
Dupilumab Versus Mepolizumab for Chronic Rhinosinusitis With Nasal Polyposis: An Indirect Treatment Comparison. PMID: 39326524
Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status. PMID: 33993501
Dupilumab for treatment of atopic dermatitis. PMID: 29557246
Dupilumab: First Global Approval. PMID: 28547386
详情请咨询Antibodysystem中国授权总代理-武汉佰乐博生物技术有限公司
网址：https://www.biolabreagent.com/
武汉佰乐博生物技术有限公司作为法国Antibodysystem品牌亚洲区授权总代理。提供近3万种蛋白、抗体等核心生命科学试剂，旨在为生命科学科研工作者提供专业、全面、可靠的试剂产品。
试剂 | 耗材 | 定制 | 实验服务 | 供应链
免费热线：027-65279366 /18108604356
